RXO INC (RXO) Fundamental Analysis & Valuation

NYSE:RXO • US74982T1034

13.74 USD
-1.71 (-11.07%)
Last: Mar 6, 2026, 08:04 PM

This RXO fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

2

Overall RXO gets a fundamental rating of 2 out of 10. We evaluated RXO against 42 industry peers in the Ground Transportation industry. RXO may be in some trouble as it scores bad on both profitability and health. While showing a medium growth rate, RXO is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

1

1. RXO Profitability Analysis

1.1 Basic Checks

  • RXO had negative earnings in the past year.
  • In the past year RXO had a positive cash flow from operations.
  • In multiple years RXO reported negative net income over the last 5 years.
  • RXO had a positive operating cash flow in 4 of the past 5 years.
RXO Yearly Net Income VS EBIT VS OCF VS FCFRXO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 2025 0 100M -100M 200M -200M 300M

1.2 Ratios

  • The Return On Assets of RXO (-3.05%) is worse than 71.43% of its industry peers.
  • The Return On Equity of RXO (-6.49%) is worse than 69.05% of its industry peers.
Industry RankSector Rank
ROA -3.05%
ROE -6.49%
ROIC N/A
ROA(3y)-3.78%
ROA(5y)0.09%
ROE(3y)-7.94%
ROE(5y)1.18%
ROIC(3y)N/A
ROIC(5y)N/A
RXO Yearly ROA, ROE, ROICRXO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 2025 0 10 -10

1.3 Margins

  • The Gross Margin of RXO (16.39%) is worse than 71.43% of its industry peers.
  • RXO's Gross Margin has declined in the last couple of years.
  • RXO does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 16.39%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-5.99%
GM growth 5Y-2.2%
RXO Yearly Profit, Operating, Gross MarginsRXO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 2025 0 5 -5 10 15

3

2. RXO Health Analysis

2.1 Basic Checks

  • RXO does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for RXO has been increased compared to 1 year ago.
  • The number of shares outstanding for RXO has been increased compared to 5 years ago.
  • The debt/assets ratio for RXO is higher compared to a year ago.
RXO Yearly Shares OutstandingRXO Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 2025 50M 100M 150M
RXO Yearly Total Debt VS Total AssetsRXO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 2025 1B 2B 3B

2.2 Solvency

  • An Altman-Z score of 2.46 indicates that RXO is not a great score, but indicates only limited risk for bankruptcy at the moment.
  • RXO has a Altman-Z score (2.46) which is comparable to the rest of the industry.
  • RXO has a Debt/Equity ratio of 0.25. This is a healthy value indicating a solid balance between debt and equity.
  • The Debt to Equity ratio of RXO (0.25) is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity 0.25
Debt/FCF N/A
Altman-Z 2.46
ROIC/WACCN/A
WACC10.67%
RXO Yearly LT Debt VS Equity VS FCFRXO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 2025 0 500M 1B 1.5B

2.3 Liquidity

  • A Current Ratio of 1.27 indicates that RXO should not have too much problems paying its short term obligations.
  • RXO has a Current ratio (1.27) which is in line with its industry peers.
  • A Quick Ratio of 1.27 indicates that RXO should not have too much problems paying its short term obligations.
  • Looking at the Quick ratio, with a value of 1.27, RXO is in line with its industry, outperforming 54.76% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.27
Quick Ratio 1.27
RXO Yearly Current Assets VS Current LiabilitesRXO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M 1B

5

3. RXO Growth Analysis

3.1 Past

  • RXO shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -145.45%.
  • The Revenue has grown by 26.20% in the past year. This is a very strong growth!
  • Measured over the past years, RXO shows a quite strong growth in Revenue. The Revenue has been growing by 11.33% on average per year.
EPS 1Y (TTM)-145.45%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-216.67%
Revenue 1Y (TTM)26.2%
Revenue growth 3Y6.18%
Revenue growth 5Y11.33%
Sales Q2Q%-11.88%

3.2 Future

  • The Earnings Per Share is expected to grow by 155.84% on average over the next years. This is a very strong growth
  • Based on estimates for the next years, RXO will show a quite strong growth in Revenue. The Revenue will grow by 9.55% on average per year.
EPS Next Y127.09%
EPS Next 2Y215.99%
EPS Next 3Y155.84%
EPS Next 5YN/A
Revenue Next Year-0.45%
Revenue Next 2Y3.01%
Revenue Next 3Y4.63%
Revenue Next 5Y9.55%

3.3 Evolution

  • The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
RXO Yearly Revenue VS EstimatesRXO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2B 4B 6B 8B 10B
RXO Yearly EPS VS EstimatesRXO Yearly EPS VS EstimatesYearly EPS VS Estimates 2022 2023 2024 2025 2026 2027 2028 0 0.5 1

1

4. RXO Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for RXO. In the last year negative earnings were reported.
  • Based on the Price/Forward Earnings ratio of 1014.46, the valuation of RXO can be described as expensive.
  • Compared to the rest of the industry, the Price/Forward Earnings ratio of RXO indicates a slightly more expensive valuation: RXO is more expensive than 64.29% of the companies listed in the same industry.
  • Compared to an average S&P500 Price/Forward Earnings ratio of 24.60, RXO is valued quite expensively.
Industry RankSector Rank
PE N/A
Fwd PE 1014.46
RXO Price Earnings VS Forward Price EarningsRXO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 200 -200 400 600 800 1K

4.2 Price Multiples

  • Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of RXO indicates a slightly more expensive valuation: RXO is more expensive than 71.43% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 24.25
RXO Per share dataRXO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 10 20 30

4.3 Compensation for Growth

  • The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates RXO does not grow enough to justify the current Price/Earnings ratio.
  • A more expensive valuation may be justified as RXO's earnings are expected to grow with 155.84% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y215.99%
EPS Next 3Y155.84%

0

5. RXO Dividend Analysis

5.1 Amount

  • RXO does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

RXO Fundamentals: All Metrics, Ratios and Statistics

RXO INC

NYSE:RXO (3/6/2026, 8:04:00 PM)

13.74

-1.71 (-11.07%)

Chartmill FA Rating
GICS SectorIndustrials
GICS IndustryGroupTransportation
GICS IndustryGround Transportation
Earnings (Last)02-06
Earnings (Next)05-05
Inst Owners108.81%
Inst Owner Change-2.09%
Ins Owners0.71%
Ins Owner Change2.16%
Market Cap2.26B
Revenue(TTM)5.74B
Net Income(TTM)-100.00M
Analysts66.92
Price Target16.4 (19.36%)
Short Float %8.29%
Short Ratio5.1
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-75.97%
Min EPS beat(2)-79.64%
Max EPS beat(2)-72.3%
EPS beat(4)1
Avg EPS beat(4)-27.69%
Min EPS beat(4)-79.64%
Max EPS beat(4)101.04%
EPS beat(8)5
Avg EPS beat(8)-6.09%
EPS beat(12)8
Avg EPS beat(12)38.1%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-2%
Min Revenue beat(2)-2.2%
Max Revenue beat(2)-1.8%
Revenue beat(4)0
Avg Revenue beat(4)-2.86%
Min Revenue beat(4)-5.04%
Max Revenue beat(4)-1.8%
Revenue beat(8)1
Avg Revenue beat(8)-1.36%
Revenue beat(12)2
Avg Revenue beat(12)-2.06%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)3.98%
PT rev (3m)3.98%
EPS NQ rev (1m)-72.8%
EPS NQ rev (3m)-121.08%
EPS NY rev (1m)-88.24%
EPS NY rev (3m)-92.96%
Revenue NQ rev (1m)-5.04%
Revenue NQ rev (3m)-5.45%
Revenue NY rev (1m)-3.2%
Revenue NY rev (3m)-3.97%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 1014.46
P/S 0.39
P/FCF N/A
P/OCF 44.23
P/B 1.46
P/tB N/A
EV/EBITDA 24.25
EPS(TTM)-0.05
EYN/A
EPS(NY)0.01
Fwd EY0.1%
FCF(TTM)-0.05
FCFYN/A
OCF(TTM)0.31
OCFY2.26%
SpS34.97
BVpS9.39
TBVpS-0.14
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -3.05%
ROE -6.49%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 16.39%
FCFM N/A
ROA(3y)-3.78%
ROA(5y)0.09%
ROE(3y)-7.94%
ROE(5y)1.18%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-5.99%
GM growth 5Y-2.2%
F-Score5
Asset Turnover1.75
Health
Industry RankSector Rank
Debt/Equity 0.25
Debt/FCF N/A
Debt/EBITDA 3.55
Cap/Depr 50.86%
Cap/Sales 1.03%
Interest Coverage N/A
Cash Conversion 46.79%
Profit Quality N/A
Current Ratio 1.27
Quick Ratio 1.27
Altman-Z 2.46
F-Score5
WACC10.67%
ROIC/WACCN/A
Cap/Depr(3y)66.04%
Cap/Depr(5y)62.51%
Cap/Sales(3y)1.22%
Cap/Sales(5y)1.13%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-145.45%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-216.67%
EPS Next Y127.09%
EPS Next 2Y215.99%
EPS Next 3Y155.84%
EPS Next 5YN/A
Revenue 1Y (TTM)26.2%
Revenue growth 3Y6.18%
Revenue growth 5Y11.33%
Sales Q2Q%-11.88%
Revenue Next Year-0.45%
Revenue Next 2Y3.01%
Revenue Next 3Y4.63%
Revenue Next 5Y9.55%
EBIT growth 1Y-123.33%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year139.58%
EBIT Next 3Y84.98%
EBIT Next 5Y60.59%
FCF growth 1Y85.96%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y525%
OCF growth 3Y-45.21%
OCF growth 5Y15.33%

RXO INC / RXO FAQ

What is the fundamental rating for RXO stock?

ChartMill assigns a fundamental rating of 2 / 10 to RXO.


What is the valuation status for RXO stock?

ChartMill assigns a valuation rating of 1 / 10 to RXO INC (RXO). This can be considered as Overvalued.


What is the profitability of RXO stock?

RXO INC (RXO) has a profitability rating of 1 / 10.


What is the expected EPS growth for RXO INC (RXO) stock?

The Earnings per Share (EPS) of RXO INC (RXO) is expected to grow by 127.09% in the next year.